Expert Opinion on Investigational Drugs

Papers
(The TQCC of Expert Opinion on Investigational Drugs is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?74
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer74
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond70
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases68
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials67
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)66
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives60
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?51
Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors51
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects50
Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases44
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success44
The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment41
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer40
Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies39
Risuteganib—a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema38
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)38
Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis38
Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas38
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis36
Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease36
Novel emerging therapies in atherosclerosis targeting lipid metabolism36
Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis36
Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis36
ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease36
The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer34
Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma32
Anti-integrin therapy for retinovascular diseases32
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential32
New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis31
Givinostat: an emerging treatment for polycythemia vera31
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis31
BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure31
Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels30
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress30
Fezolinetant in the treatment of vasomotor symptoms associated with menopause29
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer28
Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials28
Immunotherapies in clinical development for biliary tract cancer28
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs27
Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?27
New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine27
Proteasome inhibition for the treatment of glioblastoma27
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review26
Current and experimental drug therapy for the treatment of polycystic ovarian syndrome26
Monoclonal antibody therapies in the management of SARS-CoV-2 infection26
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics25
Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy24
Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development24
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action23
Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders23
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma23
Investigational drugs for the treatment of diffuse large B-cell lymphoma22
Huntingtin-lowering strategies for Huntington’s disease22
Therapies in preclinical and clinical development for Angelman syndrome22
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives21
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers21
Immunization therapies for Parkinson’s disease: state of the art and considerations for future clinical trials21
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease20
Gene-based therapy in lipid management: the winding road from promise to practice20
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?19
AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence19
Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential19
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer18
Translesion synthesis inhibitors as a new class of cancer chemotherapeutics18
The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials17
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases17
Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs17
The time to offer treatments for COVID-1917
Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)17
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia16
Anti-diabetic drugs and NASH: from current options to promising perspectives16
Melflufen for relapsed and refractory multiple myeloma16
Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials16
Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-116
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer16
CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers16
Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis15
Selective α7 nicotinic receptor agonists and positive allosteric modulators for the treatment of schizophrenia – a review15
Aromatase inhibitors for the treatment of endometriosis: a systematic review about efficacy, safety and early clinical development15
Ipilimumab: an investigational immunotherapy for glioblastoma15
Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration14
Dopamine β hydroxylase as a potential drug target to combat hypertension14
Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes14
Type I interferon antagonists in clinical development for lupus14
Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma14
Bladder cancer: shedding light on the most promising investigational drugs in clinical trials14
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development14
Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options14
Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment14
Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities14
Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease14
Post-pancreatitis diabetes mellitus: investigational drugs in preclinical and clinical development and therapeutic implications13
Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu13
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)13
Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis13
Investigational non-JAK inhibitors for chronic phase myelofibrosis13
What have we learned from past failures of investigational drugs for Alzheimer’s disease?13
Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy13
Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy13
JAK inhibitors for rheumatoid arthritis12
Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy12
Novel systemic treatment approaches for metastatic pancreatic cancer12
Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development12
Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug12
Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib12
A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?12
Emerging agents for the treatment and prevention of stroke: progress in clinical trials12
Investigational drugs in clinical trials for macular degeneration12
Emerging therapies for COVID-19 pneumonia12
An update on investigational therapies that target STAT3 for the treatment of cancer12
Current emerging and investigational drugs for the treatment of chronic hand eczema12
Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know11
New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials11
Low-dose aspirin for early COVID-19: does the early bird catch the worm?11
Telacebec: an investigational antibacterial for the treatment of tuberculosis (TB)11
Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond11
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs11
Targeting Ebola virus replication through pharmaceutical intervention11
0.030935049057007